Success Metrics

Clinical Success Rate
87.8%

Based on 36 completed trials

Completion Rate
88%(36/41)
Active Trials
2(4%)
Results Posted
50%(18 trials)
Terminated
5(10%)

Phase Distribution

Ph phase_2
9
18%
Ph phase_4
13
27%
Ph phase_3
11
22%
Ph not_applicable
9
18%
Ph phase_1
3
6%

Phase Distribution

3

Early Stage

9

Mid Stage

24

Late Stage

Phase Distribution45 total trials
Phase 1Safety & dosage
3(6.7%)
Phase 2Efficacy & side effects
9(20.0%)
Phase 3Large-scale testing
11(24.4%)
Phase 4Post-market surveillance
13(28.9%)
N/ANon-phased studies
9(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.8%

36 of 44 finished

Non-Completion Rate

18.2%

8 ended early

Currently Active

2

trials recruiting

Total Trials

49

all time

Status Distribution
Active(2)
Completed(36)
Terminated(8)
Other(3)

Detailed Status

Completed36
Terminated5
unknown3
Withdrawn3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
49
Active
2
Success Rate
87.8%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (6.7%)
Phase 29 (20.0%)
Phase 311 (24.4%)
Phase 413 (28.9%)
N/A9 (20.0%)

Trials by Status

recruiting24%
unknown36%
withdrawn36%
terminated510%
completed3673%

Recent Activity

Clinical Trials (49)

Showing 20 of 49 trialsScroll for more
NCT05922761Phase 2

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

Recruiting
NCT04885530Phase 3

ACTIV-6: COVID-19 Study of Repurposed Medications

Completed
NCT05457855

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Montelukast vs Fluticasone

Completed
NCT06705387Phase 2

Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE

Recruiting
NCT01624129

New Serological Markers for Eosinophilic Esophagitis

Unknown
NCT00763529Phase 4

Elocon vs Fluticasone in Localized Psoriasis (P03197)

Completed
NCT05736874Phase 3

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)

Completed
NCT03317015Phase 3

A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)

Completed
NCT00783224Phase 3

A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)

Completed
NCT01194622Phase 1

Single Dose Pharmacokinetics of Intranasal Fluticasone Delivered by a Fixed Combination With Azelastine (MP29 02) in Comparison to Two Different Fluticasone Nasal Sprays

Completed
NCT00929968Phase 2

Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

Completed
NCT01881412Not Applicable

Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma

Terminated
NCT01702701Phase 3

Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone

Withdrawn
NCT00830505Phase 4

Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma

Completed
NCT00829257Phase 4

Additive Effects of QVAR to (Seretide) on Surrogate Markers of Airway Inflammation in Refractory Asthma

Completed
NCT03781596Phase 4

EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone

Unknown
NCT02577497Phase 4

Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma

Completed
NCT01846962Phase 4

Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis

Completed
NCT00695604Phase 2

Repeated High-dose Inhaled Corticosteroids for Asthma

Withdrawn
NCT00214019Not Applicable

The Effect of Salmeterol on Eosinophil (EOS) Function

Completed

Drug Details

Intervention Type
DRUG
Total Trials
49